FDA ap­proves Fer­ring's new gene ther­a­py for blad­der can­cer

Fol­low­ing a CRL in May 2021 due to CMC is­sues, the FDA this af­ter­noon an­nounced the ap­proval of Fer­ring’s ade­n­ovi­ral vec­tor-based gene ther­a­py Ad­sti­ladrin …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER